Vitamin D3

What is Vitamin D3?

Vitamin D3 (cholecalciferol) is the form of vitamin D synthesised in human skin upon UV-B exposure and the supplemental form with the greatest efficacy for raising serum 25(OH)D levels. It is technically a steroid hormone precursor — converted by the liver to 25-hydroxyvitamin D and then by the kidneys and immune cells to the active form 1,25-dihydroxyvitamin D (calcitriol), which binds the vitamin D receptor (VDR) found on virtually every cell type in the body. VDR activation regulates approximately 3% of the human genome — around 200 genes — making vitamin D3 one of the most genomically influential micronutrients identified.

Immune System Mechanism

VDR expression is found on all key immune cell types: T cells, B cells, macrophages, dendritic cells, and natural killer cells. Vitamin D3 activates production of cathelicidin and defensin — antimicrobial peptides that directly destroy bacterial and viral pathogens. It also modulates the Th1/Th2 balance, reducing excessive inflammatory cytokine production that drives severe infection outcomes. A landmark meta-analysis of 46 RCTs by Martineau et al. (BMJ, 2017) found supplementation reduced acute respiratory infection risk by 12% overall — rising to 70% risk reduction in those with severe baseline deficiency (OR 0.30).

Cancer Prevention Evidence

The VITAL trial (25,871 US adults, 2000 IU/day, 5.3 years) — the largest RCT of vitamin D for cancer prevention — found no significant reduction in overall cancer incidence but demonstrated compelling signals for cancer mortality: HR 0.83 at 5 years, strengthening to HR 0.75 (25% reduction) when excluding the first two years of follow-up to account for latency. A 2024 umbrella review of 71 systematic reviews (Petrelli et al., Clinical Nutrition ESPEN) confirmed strong evidence for vitamin D3 reducing total cancer mortality (OR 0.90, p<0.01) and highly suggestive evidence for reducing head/neck, breast, colorectal, lung, and renal cancers. The DKFZ meta-analysis (14 RCTs, over 100,000 participants) found daily D3 at physiologic doses reduced cancer mortality by 12% overall, rising to 20% in deficient cohorts.

Who Is Deficient?

Over 40% of UK adults are estimated to be vitamin D deficient (<20 ng/mL serum 25(OH)D) — rising to over 70% in South Asian and African-Caribbean populations with darker skin pigmentation. Northern latitude, indoor working, sun avoidance, and obesity all reduce cutaneous synthesis. The NHS recommends 400 IU daily for the general population, but most clinical researchers consider this insufficient to raise deficient individuals to optimal levels — which require 1000–2000 IU daily in adults.

Optimal Dosing

For adults with confirmed or likely deficiency: 1000–2000 IU D3 daily, ideally with a meal containing fat (D3 is fat-soluble). Testing serum 25(OH)D before supplementing allows targeted dosing. Target level for cancer prevention and immune benefits: 40–60 ng/mL. Bolus dosing (monthly high-dose) is less effective than daily supplementation for sustaining receptor activation. Vitamin K2 (MK-7 form) is often co-supplemented to direct calcium appropriately.